您当前所在位置: 首页 > 产品中心 > 抗体

单克隆抗体

PAI-1 Human Antibody

op

★Download Datasheet★

Monoclonal Antibody against Human PAI-1 (Clone 3H3)
Size: 0.1 mg


Introduction
Plasminogen activator inhibitor-1 (PAI-1) is the primary inhibitor of tissue-type and urokinase-type plasminogen activator, playing a major role in fibrinolysis [1,2]. PAI-1 is mainly produced by the endothelium, but is also secreted by other tissue types, such as adipose tissue [3]. It is normally present at low levels in plasma and tissue, but its expression and release are increased in various disease states (such as a number of forms of cancer), as well as in obesity and the metabolic syndrome [4]. PAI-1 is also involved in the pathophysiology of renal, pulmonary, cardiovascular, and metabolic diseases [5-8]. Elevated local or systemic PAI-1 can also exacerbate such pathologic conditions.

Purification

Protein G affinity purification

Immunogen

Recombinant human PAI-1 expressed in E.coli.

Specificity

The antibody detects human PAI-1.

Formulation

Liquid in phosphate-buffered saline (PBS).

Storage

Store at –20°C for less than one week. For long-term storage, aliquot and freeze at -70°C. Avoid repeated freeze/defrost cycles.

Application/Usage

This antibody can be used as a capture antibody in a human PAI-1 ELISA in combination with polyclonal anti-human PAI-1 antibody as detection antibody.

References

1. Lijnen HR, et al. (1995) Baillieres Clin Haematol. 8: 277–290

2. Dellas C, et al. (2005) Thromb Haemost. 2005; 93: 631–640

3. Binder BR, et al. (2002) News Physiol Sci 17:56-61

4. Vague P, et al. (1986) Metabolism. 35: 250–253

5. Sobel Be, et al. (2003) Arterioscler Thromb Vasc Biol. 23: 1979–1989

6. Eitzman DT, et al. (1996) J Clin Invest. 97(1):232-7

7. Gils A, et al. (2004) Thromb. Haemost. 91 (3): 425–37

8. Cale JM, Lawrence DA. (2007) Curr Drug Targets. 8(9):971-81